FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979580249> ?p ?o ?g. }

• W2979580249 endingPage "S478" @default.
• W2979580249 startingPage "S478" @default.
• W2979580249 abstract "INTRODUCTION: Tofacitinib was FDA approved in 2018 for use in patients with moderate to severe ulcerative colitis (UC). It is an oral inhibitor of Janus-kinase 1-3 and can be used in patients who are naïve or have failed other biological therapies. We conducted a systematic review and meta-analysis to assess the overall clinical response and remission of Tofacitinib in patients with moderate-severe UC. METHODS: We conducted a comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Web of Science databases, Google Scholar and manual search of references (from inception through October 2018) to identify studies that reported use of Tofacitinib in moderate-severe UC patients. The primary outcome was to look at the clinical response and remission and secondary outcome was to look for adverse events. Clinical response was defined as an absolute decrease of Mayo-score by at least 3 points and a relative decrease by at least 30%-with an accompanying decrease in rectal bleeding sub score of at least 1 point or an absolute rectal bleeding sub score of 0 to 1. Clinical remission was defined as total Mayo score of 0 to 2, with no individual sub score exceeding 1. The meta-analysis was performed using Der Simonian and Laird random effect model. RESULTS: A total of 6 studies reporting on 1207 patients receiving 10 mg of Tofacitinib were included in our final meta- analysis. The mean age and follow up were 41.5 years and 15.4 months respectively. 497 patients and 627 patients (using 5/6 studies) were TNF inhibitors naïve and experienced respectively. The overall pooled clinical response and clinical remission of Tofacitinib in moderate-severe UC was 59.68% (95% CI = 55.3- 63.57, I 2 = 31.92%) and 31.61% (95% CI = 20.78-43.52, I 2 = 92.77%) respectively (Tables 1 and 2). The overall adverse events were 706, which mainly included infections with 22.73% [95% CI = 15.51- 30.83, I 2 = 86.13%). The cumulative incidence of Herpes zoster was 0.6% (95% CI = 0.0-2.24, I 2 = 67.21%). Significant heterogeneity was noted in the studies included in our meta-analysis. CONCLUSION: Based on the limited data included in our meta-analysis, Tofacitinib (10 mg) seems to have good overall clinical response rate of 59.68%. There was higher rate of infections noted in our meta-analysis. Overall low incidence of Herpes zoster could be due to short follow up (4/6 studies). Further multi-center studies are needed to assess long-term efficacy and safety of Tofacitinib in moderate-severe ulcerative colitis patients." @default.
• W2979580249 created "2019-10-18" @default.
• W2979580249 creator A5010060065 @default.
• W2979580249 creator A5026934400 @default.
• W2979580249 creator A5033534461 @default.
• W2979580249 creator A5035013087 @default.
• W2979580249 creator A5053117866 @default.
• W2979580249 creator A5056317091 @default.
• W2979580249 creator A5066014108 @default.
• W2979580249 creator A5073357054 @default.
• W2979580249 creator A5085514125 @default.
• W2979580249 date "2019-10-01" @default.
• W2979580249 modified "2023-09-23" @default.
• W2979580249 title "827 Efficacy and Safety of Tofacitinib in Moderate-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis" @default.
• W2979580249 doi "https://doi.org/10.14309/01.ajg.0000592844.90451.64" @default.
• W2979580249 hasPublicationYear "2019" @default.
• W2979580249 type Work @default.
• W2979580249 sameAs 2979580249 @default.
• W2979580249 citedByCount "0" @default.
• W2979580249 crossrefType "journal-article" @default.
• W2979580249 hasAuthorship W2979580249A5010060065 @default.
• W2979580249 hasAuthorship W2979580249A5026934400 @default.
• W2979580249 hasAuthorship W2979580249A5033534461 @default.
• W2979580249 hasAuthorship W2979580249A5035013087 @default.
• W2979580249 hasAuthorship W2979580249A5053117866 @default.
• W2979580249 hasAuthorship W2979580249A5056317091 @default.
• W2979580249 hasAuthorship W2979580249A5066014108 @default.
• W2979580249 hasAuthorship W2979580249A5073357054 @default.
• W2979580249 hasAuthorship W2979580249A5085514125 @default.
• W2979580249 hasConcept C126322002 @default.
• W2979580249 hasConcept C168563851 @default.
• W2979580249 hasConcept C187960798 @default.
• W2979580249 hasConcept C197934379 @default.
• W2979580249 hasConcept C203092338 @default.
• W2979580249 hasConcept C2776233030 @default.
• W2979580249 hasConcept C2777575956 @default.
• W2979580249 hasConcept C2778886723 @default.
• W2979580249 hasConcept C2779134260 @default.
• W2979580249 hasConcept C2780479503 @default.
• W2979580249 hasConcept C71924100 @default.
• W2979580249 hasConcept C95190672 @default.
• W2979580249 hasConceptScore W2979580249C126322002 @default.
• W2979580249 hasConceptScore W2979580249C168563851 @default.
• W2979580249 hasConceptScore W2979580249C187960798 @default.
• W2979580249 hasConceptScore W2979580249C197934379 @default.
• W2979580249 hasConceptScore W2979580249C203092338 @default.
• W2979580249 hasConceptScore W2979580249C2776233030 @default.
• W2979580249 hasConceptScore W2979580249C2777575956 @default.
• W2979580249 hasConceptScore W2979580249C2778886723 @default.
• W2979580249 hasConceptScore W2979580249C2779134260 @default.
• W2979580249 hasConceptScore W2979580249C2780479503 @default.
• W2979580249 hasConceptScore W2979580249C71924100 @default.
• W2979580249 hasConceptScore W2979580249C95190672 @default.
• W2979580249 hasIssue "1" @default.
• W2979580249 hasLocation W29795802491 @default.
• W2979580249 hasOpenAccess W2979580249 @default.
• W2979580249 hasPrimaryLocation W29795802491 @default.
• W2979580249 hasRelatedWork W1991688187 @default.
• W2979580249 hasRelatedWork W2611548364 @default.
• W2979580249 hasRelatedWork W2973090228 @default.
• W2979580249 hasRelatedWork W2998896570 @default.
• W2979580249 hasRelatedWork W3028296069 @default.
• W2979580249 hasRelatedWork W3208816751 @default.
• W2979580249 hasRelatedWork W4246746494 @default.
• W2979580249 hasRelatedWork W4252865503 @default.
• W2979580249 hasRelatedWork W4283267213 @default.
• W2979580249 hasRelatedWork W4311338149 @default.
• W2979580249 hasVolume "114" @default.
• W2979580249 isParatext "false" @default.
• W2979580249 isRetracted "false" @default.
• W2979580249 magId "2979580249" @default.
• W2979580249 workType "article" @default.